Quantcast

The Puridone Program – A Breakthrough for Painkiller Addiction

June 15, 2012

Normally used in clinical settings, Puridone has been recently released to the general public online as a 60-day “in home” treatment to help those dealing with opiate dependency and painkiller addiction. In clinical studies conducted in 2012, Puridone demonstrated a remarkable increase in energy, sleep and sex drive, while simultaneously lowering withdrawal symptoms, anxiety and depression scores.

Jamison, PA (PRWEB) June 15, 2012

The Puridone Program is an incredible new proprietary formula with patent-pending technology that gives hope to anyone dealing with the stress and discomfort of withdrawing from painkillers and opiates. The Physicians for Responsible Opioid Prescribing report that 25% of those on opioid medication (routinely prescribed after surgeries or injuries) meet criteria for addiction. Through no fault of their own, individuals can find themselves physically addicted to these commonly used medications, wreaking havoc on their health and mental well-being, as well as their family and work life.

The only way to heal from painkiller addiction is to stop using them, but dependence can happen after even a short time. Once a person has begun coping with uncomfortable feelings and sensations by using opiates, attempting to come off of these medications can often be fraught with difficult and intensely uncomfortable side effects, including:

*Agitation *Anxiety *Constipation *Loss of sex drive *Cravings *Depression *Fatigue *Muscle aches *Increased tearing *Insomnia *Sweating

Puridone was designed for this exact purpose, and unlike offsite detox programs, Puridone can be safely used in the comfort of your own home. Puridone eases these symptoms, allowing the body to achieve a successful recovery. Containing a synergistic blend of 14 herbs, and 23 vitamins and minerals, Puridone has been specifically designed to both increase overall health and combat the very symptoms of opiate withdrawal that make it so hard for people to quit.

Puridone´s unique formula, which contains B-Vitamins, Calcium, Magnesium, Vitamin-C, and Choline, all work together with herbs such as Skullcap, Gotu Kola, Eleuthero, and Passion Flower to help the body achieve mental and physical balance. Individuals taking Puridone have demonstrated improved energy and mental alertness as well as better sleep, lower anxiety and increase sex drive. Puridone helps accomplish this without the use of stimulants.

Nearly a decade of research has gone into this groundbreaking formula, but even the best solution can´t provide benefit if it can´t be effectively absorbed by the body. Puridone enables its incredible rates of absorption and efficacy by using a nano-encapsulation delivery system that reduces the particle size of the ingredients, dramatically increasing absorption rates by up to 400%.

Molecules of the active compounds are separated and enveloped in all-natural encapsulation material, maintaining the compounds´ nano-size for the most efficient use by the body. Unlike many other encapsulating materials, Puridone uses all natural plant lipids, which are a food grade material. There is no danger of any adverse response from the body, the material delivers its payload and then is completely metabolized just like any other food based particles would be.

In a third-party study verifying the efficacy of Puridone, study participants showed dramatic improvement in levels of anxiety and depression, as well as increased mental alertness, decreased levels of stress, increased energy and improvements in quality of sleep. Dr. Stewart Alan Kauffman from the Philadelphia College of Osteopathic Medicine reports, “In my pain management practice I work with professionals, sports figures, medical students, and even young people at my children´s high school – all suffering from opiate addiction. I can safely and confidently recommend the Puridone Program to anyone dealing with painkiller dependency.”

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/6/prweb9607340.htm


Source: prweb



comments powered by Disqus